An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
The clinical development of an inhibitor of cellular proteasome function suggests that compounds targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies. NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome. Substrates of cullin-RING ligases have important roles in cellular processes associated with cancer cell growth and survival pathways. Here we describe MLN4924, a potent and selective inhibitor of NAE. MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumour cells by a new mechanism of action, the deregulation of S-phase DNA synthesis. MLN4924 suppressed the growth of human tumour xenografts in mice at compound exposures that were well tolerated. Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“orthogonally confirmed dose-dependent KAT2A degradation by western blot, and demonstrated that this degradation can be rescued by pre-treatment with a UBA3/NAE1 inhibitor, MLN4924 (37), a proteasome inhibitor, bortezomib (38), and a competing CRBN ligand, pomalidomide (7) (Fig. 1D).”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [37]
In the citing paper
“we cotreated cells with a proteasome inhibitor (bortezomib) or a NEDD8-activating enzyme E1 inhibitor (MLN-4924 32 ) and found that both inhibitors prevented degradation of BTK (Figure 2D).”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [32]
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Self-citationKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins
Kerscher, O., Felberbaum, R., & Hochstrasser, M. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010605.093503 · Cited by 1,517
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., & Harper, J. W. (1999) · Genes & Development · doi:10.1101/gad.13.3.270 · Cited by 954
Duda, D. M., Borg, L. A., Scott, D. C., Hunt, H. W., Hammel, M., & Schulman, B. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.022 · Cited by 767
Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R. C., & Conaway, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190332597 · Cited by 653
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-508 · Cited by 628
Cited by
Items 501–600 of 1,005
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase
Degorce, S. L., Tavana, O., Banks, E., Crafter, C., Gingipalli, L., Kouvchinov, D., Mao, Y., Pachl, F., Solanki, A., Valge-Archer, V., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01125 · Cited by 48
CSNAP Is a Stoichiometric Subunit of the COP9 Signalosome
Rozen, S., Füzesi-Levi, M. G., Ben‐Nissan, G., Mizrachi, L., Gabashvili, A., Levin, Y., Ben‐Dor, S., Eisenstein, M., & Sharon, M. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.021 · Cited by 56
CAR Suppresses Hepatic Gluconeogenesis by Facilitating the Ubiquitination and Degradation of PGC1α
Gao, J., Yan, J., Xu, M., Ren, S., & Xie, W. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1145 · Cited by 57
Bailly, A., Perrin, A., Malhab, L. J. B., Pion, E., Larance, M., Nagala, M., Smith, P. G., O’Donohue, M.-F., Gleizes, P., Zomerdijk, J. C. B. M., et al. (2015) · Oncogene · doi:10.1038/onc.2015.104 · Cited by 58
Self-citationFlexible Cullins in Cullin-RING E3 Ligases Allosterically Regulate Ubiquitination
Liu, J., & Nussinov, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277236 · Cited by 52
Shibata, E., Dar, A., & Dutta, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.574210 · Cited by 56
Xu, J., Li, L., Yu, G., Ying, W., Gao, Q., Zhang, W., Li, X., Ding, C., Jiang, Y., Wei, D., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.045211 · Cited by 57
Zhang, Y., Shi, C., Zhang, H., Li, G.-Q., & Li, S. (2016) · Oncotarget · doi:10.18632/oncotarget.9481 · Cited by 56
Wu, F., Dai, X., Gan, W., Wan, L., Li, M., Mitsiades, N., Wei, W., Ding, Q., & Zhang, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.021 · Cited by 61
Self-citationInhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo
Asare, Y., Ommer-Bläsius, M., Azombo, F. A., Alampour‐Rajabi, S., Sternkopf, M., Sanati, M., Gijbels, M. J., Schmitz, C., Sinitski, D., Tilstam, P. V., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618411114 · Cited by 58
Paiva, C. J., Godbersen, J. C., Berger, A., Brown, J. R., & Danilov, A. V. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.161 · Cited by 56
Self-citationWu, D., Li, H., Liu, M., Qin, J., & Sun, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-30707-8 · Cited by 59
Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
McMillin, D. W., Jacobs, H. M., Delmore, J. E., Buon, L., Hunter, Z. R., Monrose, V., Yu, J., Smith, P. G., Richardson, P. G. G., Anderson, K. C., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0563 · Cited by 55
Self-citationAn inhibitor of ubiquitin conjugation and aggresome formation
An, H., & Statsyuk, A. V. (2015) · Chemical Science · doi:10.1039/c5sc01351h · Cited by 58
Suramin inhibits cullin-RING E3 ubiquitin ligases
Wu, K., Chong, R. A., Yu, Q., Bai, J., Spratt, D. E., Ching, K., Lee, C., Miao, H., Tappin, I., Hurwitz, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601089113 · Cited by 62
Li, Y., Sun, Q., Zhao, T.-Y., Xiang, H., Zhang, X., Wu, Z.-Y., Zhou, C.-J., Zhang, X., Wang, Y., Zhang, Y., et al. (2019) · New Phytologist · doi:10.1111/nph.15702 · Cited by 55
Self-citationZhang, X., Zhang, Y., Qiu, G.-H., Pian, L., Guo, L., Cao, H., Liu, J., Zhao, Y., Li, X., Xu, Z. Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910765117 · Cited by 56
Self-citationDiscovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders
Chen, L., Chen, Y., Zhang, C., Jiao, B., Liang, S., Qiong, T., Chai, H., Yu, W., Qian, Y., Yang, H., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01342 · Cited by 56
Self-citationFei, X., Li, Z., Yang, D., Kong, X., Lu, X., Shen, Y., Li, X., Xie, S., Wang, J., Zhao, Y., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12153 · Cited by 58
Self-citationDesign, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders
Yu, X., Xu, J., Xie, L., Wang, L., Shen, Y., Cahuzac, K. M., Chen, X., Liu, J., Parsons, R. E., & Jin, J. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01476 · Cited by 57
Targeting ubiquitination in disease and therapy
Yang, X., Lan, T., Zhang, B., Tao, X., Qi, W., Xie, K., Cai, Y., Liu, C., Han, J., & Wu, H. M. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02392-8 · Cited by 66
Taieb, F. E., Nougayrède, J., & Oswald, É. (2011) · Toxins · doi:10.3390/toxins3040356 · Cited by 54
Characterization of the mammalian family of DCN-type NEDD8 E3 ligases
Keuss, M. J., Thomas, Y., McArthur, R., Wood, N. T., Knebel, A., & Kurz, T. (2016) · Journal of Cell Science · doi:10.1242/jcs.181784 · Cited by 54
Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease
Rodríguez‐Muela, N., Litterman, N. K., Norabuena, E. M., Mull, J. L., Galazo, M. J., Sun, C., Ng, S., Makhortova, N. R., White, A. J., Lynes, M. M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.035 · Cited by 55
Wu, M., Lee, C., Huang, T., Huang, K., Tang, C., Liu, S., Kuo, K.-L., Kuan, F., Lin, W., & Shi, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010072 · Cited by 54
SCF FBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis
Bai, J., Wu, K., Cao, M., Yang, Y., Pan, Y., Liu, H., He, Y. J., Itahana, Y., Huang, L., Zheng, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820990116 · Cited by 58
Burdová, K., Yang, H., Faedda, R., Hume, S., Chauhan, J. S., Ebner, D. V., Kessler, B. M., Vendrell, I., Drewry, D. H., Wells, C. I., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018101443 · Cited by 56
Nedd8 Regulates Inflammasome-Dependent Caspase-1 Activation
Segovia, J. A., Tsai, S.-Y., Chang, T.-H., Shil, N. K., Weintraub, S. T., Short, J. D., & Bose, S. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00775-14 · Cited by 55
A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis
Du, C., Hansen, L. J., Singh, S. X., Wang, F., Sun, R., Moure, C. J., Roso, K., Greer, P. K., Yan, H., & He, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.031 · Cited by 54
Beider, K., Rosenberg, E., Voevoda, V., Sirovsky, Y., Vladimirsky, J., Magen, H., Ostrovsky, O., Shimoni, A., Bromberg, Z., Weiss, L., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00993-0 · Cited by 59
Zhou, H., Lü, J., Chinnaswamy, K., Stuckey, J. A., Liu, L., McEachern, D., Yang, C., Bernard, D., Shen, H., Rui, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22924-4 · Cited by 53
Pakjoo, M., Ahmadi, S. E., Zahedi, M., Jaafari, N., Khademi, R., Amini, A., & Safa, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01433-5 · Cited by 58
Vringer, E., Heilig, R., Riley, J. S., Black, A. R. S., Cloix, C., Skalka, G., Montes-Gómez, A. E., Aguado, A., Lilla, S., Walczak, H., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00044-1 · Cited by 56
Ubiquitin-Specific Proteases as Cancer Drug Targets
Sippl, W., Collura, V., & Colland, F. (2011) · Future Oncology · doi:10.2217/fon.11.39 · Cited by 55
Targeting Protein Neddylation for Cancer Therapy
Zhou, L., & Jia, L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_18 · Cited by 53
Diverse and pivotal roles of neddylation in metabolism and immunity
Zou, T., & Zhang, J. (2020) · FEBS Journal · doi:10.1111/febs.15584 · Cited by 55
Self-citationUbiquitination and the Proteasome as Drug Targets in Trypanosomatid Diseases
Bijlmakers, M.-J. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2020.630888 · Cited by 56
Decoding the messaging of the ubiquitin system using chemical and protein probes
Henneberg, L. T., & Schulman, B. A. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.009 · Cited by 56
Hu, R., Wang, W., Yang, Y.-Y., Hu, X.-T., Wang, Q., Zuo, W., Xu, Y., Feng, Q., & Wang, N. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113922 · Cited by 55
Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
Dang, F., Nie, L., Zhou, J. R., Shimizu, K., Chu, C., Wu, Z., Fassl, A., Ke, S., Wang, Y., Zhang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25700-6 · Cited by 52
Self-citationNeddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism
Gonzalez-Rellan, M. J., Fernandez, U., Parracho, T., Nóvoa, E., Fondevila, M. F., Lima, N. D. S., Ramos, L., Rodríguez, A., Serrano‐Maciá, M., Pérez‐Mejías, G., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.003 · Cited by 55
A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation
Basu, A. A., Zhang, C., Riha, I. A., Magassa, A., Campos, M. A. L., Caldwell, A. G., Ko, F., & Zhang, X. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01655-9 · Cited by 55
Ren, W., Fu, C.-L., Zhang, Y., Ju, X., Jiang, X., Song, J., Gong, M., Li, Z., Fan, W., Yao, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403235121 · Cited by 57
Garcia, K., Blank, J. L., Bouck, D. C., Liu, X. J., Sappal, D. S., Hather, G., Cosmopoulos, K., Thomas, M. P., Kuranda, M., Pickard, M. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0634 · Cited by 52
Self-citationColeman, K. E., Békés, M., Chapman, J. R., Crist, S. B., Jones, M. V., Ueberheide, B. M., & Huang, T. T. (2017) · eLife · doi:10.7554/elife.24325 · Cited by 53
Ubiquitin-like modifications in the DNA damage response
Wang, Z., Zhu, W., & Xu, X. (2017) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2017.07.001 · Cited by 53
Targeting adenylate-forming enzymes with designed sulfonyladenosine inhibitors
Lux, M. C., Standke, L. C., & Tan, D. S. (2019) · The Journal of Antibiotics · doi:10.1038/s41429-019-0171-2 · Cited by 55
Serrano‐Maciá, M., Simón, J., Gonzalez-Rellan, M. J., Azkargorta, M., Goikoetxea‐Usandizaga, N., Lopitz‐Otsoa, F., de Urturi, D. S., Agudo, R. R., Lachiondo‐Ortega, S., Mercado-Gómez, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101275 · Cited by 53
Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy
Xie, S. C., Metcalfe, R. D., Dunn, E. A., Morton, C. J., Huang, S., Puhalovich, T., Du, Y., Wittlin, S., Nie, S., Luth, M. R., et al. (2022) · Science · doi:10.1126/science.abn0611 · Cited by 55
Self-citationBarghout, S. H., Aman, A. M., Nouri, K., Blatman, Z., Arevalo, K., Thomas, G. E., MacLean, N., Hurren, R., Ketela, T., Saini, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141518 · Cited by 51
Proteomic characterization of post-translational modifications in drug discovery
Zhai, L., Chen, K., Hao, B., & Tan, M. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01017-y · Cited by 59
Targeting cullin neddylation for cancer and fibrotic diseases
He, Z., Yang, W.-G., Dan, Z., Gao, G., Zhang, Q., Liu, H., Wen, Z., & Ma, L. (2023) · Theranostics · doi:10.7150/thno.78876 · Cited by 51
Nawrocki, S. T., Kelly, K. R., Smith, P. G., Keaton, M., Carraway, H. E., Sekeres, M. A., Maciejewski, J. P., & Carew, J. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1960 · Cited by 52
Self-citationMorikawa, H., Kim, M., Mimuro, H., Claire, P., Koyama, T., Nagai, S., Miyawaki, A., Iwaï, K., & Sasakawa, C. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.048 · Cited by 52
Tan, M., Xu, J., Siddiqui, J., Feng, F. Y.-C., & Sun, Y. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0567-6 · Cited by 52
Jang, S., Zhang, Y., Utani, K., Fu, H., Redon, C. E., Marks, A. B., Smith, O. K., Redmond, C. J., Baris, A. M., Tulchinsky, D. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05177-6 · Cited by 53
Discovery of small-molecule candidates against inflammatory bowel disease
Bai, R., Jie, X., Yao, C., & Xie, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111805 · Cited by 52
Activation of the CARD8 Inflammasome Requires a Disordered Region
Chui, A. J., Griswold, A. R., Taabazuing, C. Y., Orth-He, E. L., Gai, K., Rao, S. D., Ball, D. P., Hsiao, J. C., & Bachovchin, D. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108264 · Cited by 58
Neddylation regulation of mitochondrial structure and functions
Zhou, Q., Zheng, Y., & Sun, Y. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00569-6 · Cited by 51
Zhang, J., Cui, J. R., Zhao, F., Yang, L., Xu, X., Shi, Y., & Wei, B. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102114 · Cited by 54
Self-citationLi, Y.-J., Du, L., Wang, J., Vega, R., Lee, T. D., Miao, Y., Aldana-Masangkay, G., Samuels, E. R., Li, B., Ouyang, S. X., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.026 · Cited by 50
Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics
Pal, S., Sharma, A. K., Mathew, S. P., & Jaganathan, B. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955476 · Cited by 56
The Role of the COP9 Signalosome and Neddylation in DNA Damage Signaling and Repair
Chung, D., & Dellaire, G. (2015) · Biomolecules · doi:10.3390/biom5042388 · Cited by 53
Ehrentraut, S., Kominsky, D. J., Glover, L. E., Campbell, E. L., Kelly, C. J., Bowers, B., Bayless, A. J., & Colgan, S. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202041 · Cited by 51
The ubiquitin pathway: An emerging drug target in cancer therapy
Ande, S. R., Chen, J., & Maddika, S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.042 · Cited by 52
Kapuria, V., Peterson, L. F., Showalter, H. D., Kirchhoff, P. D., Talpaz, M., & Donato, N. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.012 · Cited by 52
Mechanistic Study of Uba5 Enzyme and the Ufm1 Conjugation Pathway
Gavin, J. M., Hoar, K. M., Xu, Q., Ma, J., Lin, Y., Chen, J., Chen, W., Bruzzese, F. J., Harrison, S., Mallender, W. D., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.573972 · Cited by 50
Self-citationProteasome‐mediated proteostasis: Novel medicinal and pharmacological strategies for diseases
Mishra, R., Upadhyay, A., Prajapati, V. K., & Mishra, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21502 · Cited by 51
Liu, M., Jiang, K., Lin, G., Liu, P., Yan, Y., Tian, Y., Yao, G., Barr, M. P., Liang, D., Wang, Y., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0806-3 · Cited by 57
Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1–UBE2M Interaction
Zhou, W., Ma, L., Ding, L., Guo, Q., He, Z., Yang, J. C., Qiao, H., Li, L., Yang, J., Yu, S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00003 · Cited by 51
The cross talk of two family members of β-TrCP in the regulation of cell autophagy and growth
Cui, D., Dai, X.-Q., Shu, J., Ma, Y., Wei, D., Xiong, X., & Zhao, Y. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0402-x · Cited by 53
The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications
Sang, Y., Fan, Y., & Ren, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6052 · Cited by 56
Joehnk, B., Bayram, Ö., Abelmann, A., Heinekamp, T., Mattern, D. J., Brakhage, A. A., Jacobsen, I. D., Valerius, O., & Braus, G. H. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005899 · Cited by 50
Advances in Cancer Treatment by Targeting the Neddylation Pathway
Gai, W., Peng, Z., Liu, C. H., Zhang, L., & Jiang, H. F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.653882 · Cited by 50
USP15 antagonizes CRL4 CRBN -mediated ubiquitylation of glutamine synthetase and neosubstrates
Nguyen, T. V. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111391118 · Cited by 53
Modification by Ubiquitin-Like Proteins: Significance in Apoptosis and Autophagy Pathways
Cajee, U.-F., Hull, R., & Ntwasa, M. M. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911804 · Cited by 54
Protein folding, protein homeostasis, and cancer
Drie, J. H. V. (2011) · 癌症:英文版 · doi:10.5732/cjc.010.10162 · Cited by 55
Identification and Mechanistic Studies of a Novel Ubiquitin E1 Inhibitor
Ungermannova, D., Parker, S. J., Nasveschuk, C. G., Chapnick, D. A., Phillips, A. J., Kuchta, R. D., & Liu, X. (2012) · SLAS DISCOVERY · doi:10.1177/1087057111433843 · Cited by 48
Liao, Y., Jiang, Y., He, H., Ni, H., Tu, Z., Zhang, S., Wang, B. J., Lou, J., Quan, S., & Wang, H. (2015) · Human Reproduction · doi:10.1093/humrep/dev117 · Cited by 48
Dynamic ubiquitination drives herpesvirus neuroinvasion
Huffmaster, N. J., Sollars, P. J., Richards, A. L., Pickard, G. E., & Smith, G. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512559112 · Cited by 48
Broad and potent antiviral activity of the NAE inhibitor MLN4924
Le‐Trilling, V. T. K., Megger, D. A., Katschinski, B., Landsberg, C. D., Rückborn, M. U., Tao, S., Krawczyk, A., Bayer, W., Drexler, I., Tenbusch, M., et al. (2016) · Scientific Reports · doi:10.1038/srep19977 · Cited by 48
Scherer, P. C., Ding, Y., Liu, Z., Xu, J., Mao, H., Barrow, J. C., Wei, N., Zheng, N., Snyder, S. H., & Rao, F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525580113 · Cited by 48
Neutrophils and inflammatory resolution in the mucosa
Colgan, S. P. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.007 · Cited by 51
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
Cooper, J. M., Xu, Q., Zhou, L., Pavlović, M., Ojeda, V., Moulick, K., de Stanchina, E., Poirier, J. T., Zauderer, M. G., Rudin, C. M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0821 · Cited by 53
Akgül, S., Li, Y., Zheng, S., Kool, M., Treisman, D. M., Li, C., Wang, Y., Gröbner, S. N., Ikenoue, T., Shen, Y., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.050 · Cited by 51
Algal photoprotection is regulated by the E3 ligase CUL4–DDB1DET1
Aihara, Y., Fujimura‐Kamada, K., Yamasaki, T., & Minagawa, J. (2018) · Nature Plants · doi:10.1038/s41477-018-0332-5 · Cited by 50
Xie, C.-M., Tan, M., Lin, X.-T., Wu, D., Jiang, Y., Tan, Y., Li, H., Ma, Y., Xiong, X., & Sun, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.052 · Cited by 49
Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy
Aubry, A., Tao, Y., & Bremner, R. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0237-8 · Cited by 48
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031096 · Cited by 49
HERC5-catalyzed ISGylation potentiates cGAS-mediated innate immunity
Chu, L., Qian, L., Chen, Y., Duan, S., Ding, M., Sun, W., Meng, W., Zhu, J., Wang, Q., Hao, H., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113870 · Cited by 50
Adenosine and gastrointestinal inflammation
Colgan, S. P., Fennimore, B. P., & Ehrentraut, S. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0990-0 · Cited by 47
Ubiquitination involved enzymes and cancer
Zhou, M., Chen, F., & Chen, H. (2014) · Medical Oncology · doi:10.1007/s12032-014-0093-6 · Cited by 50
Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics
Lill, J. R., & Wertz, I. E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.005 · Cited by 52
Hughes, D. J., Wood, J. J., Jackson, B. R., Baquero-Pérez, B., & Whitehouse, A. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004771 · Cited by 47
Identification of Sumoylation Activating Enzyme 1 Inhibitors by Structure-Based Virtual Screening
Kumar, A., Ito, A., Hirohama, M., Yoshida, M., & Zhang, K. Y. J. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300618e · Cited by 49
Balachandran, R. S., Heighington, C. S., Starostina, N. G., Anderson, J. W., Owen, D. L., Vasudevan, S., & Kipreos, E. T. (2016) · The Journal of Cell Biology · doi:10.1083/jcb.201601083 · Cited by 50
Hammill, J. T., Scott, D. C., Min, J., Connelly, M., Holbrook, G., Zhu, F., Matheny, A., Yang, L., Singh, B., Schulman, B. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01277 · Cited by 48
Unanchored tri‐NEDD8 inhibits PARP‐1 to protect from oxidative stress‐induced cell death
Keuss, M. J., Hjerpe, R., Hsia, O., Gourlay, R., Burchmore, R., Trost, M., & Kurz, T. (2019) · The EMBO Journal · doi:10.15252/embj.2018100024 · Cited by 47
Chen, P., Hu, T., Liang, Y., Jiang, Y., Pan, Y., Li, C., Zhang, P., Wei, D., Li, P., Jeong, L. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3282 · Cited by 47
HIV relies on neddylation for ubiquitin ligase-mediated functions
Nekorchuk, M. D., Sharifi, H. J., Furuya, A. K. M., Jellinger, R. M., & de Noronha, C. M. C. (2013) · Retrovirology · doi:10.1186/1742-4690-10-138 · Cited by 47
Metadata
- Authors
- Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., Cullis, C. A., Doucette, A., Garnsey, J. J., Gaulin, J. L., Gershman, R. E., Lublinsky, A. R., McDonald, A., Mizutani, H., Narayanan, U., Olhava, E. J., Peluso, S., Rezaei, M., Sintchak, M. D., Talreja, T., Thomas, M. P., Traore, T., Vyskocil, S., Weatherhead, G. S., Yu, J., Zhang, J., Dick, L. R., Claiborne, C. F., Rolfe, M., Bolen, J. B., & Langston, S. P.
- Affiliations
- Takeda Oncology (United States) (US)
- Corresponding author
- Soucy, Teresa A.
- ORCID
- Venue
- Nature
- Published
- 2009-04
- Volume
- 458
- Issue
- 7239
- Pages
- 732-736
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2076194625
- Cited by
- 1,990
- References
- 46
- Citations by year
- 2026: 110 · 2025: 120 · 2024: 156 · 2023: 126 · 2022: 137 · 2021: 155 · 2020: 170 · 2019: 149 · 2018: 112 · 2017: 105 · 2016: 108 · 2015: 98 · 2014: 99 · 2013: 100 · 2012: 100
- FWCI
- 32.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- NEDD8-activating enzyme, MLN4924, cullin-RING ubiquitin ligases, ubiquitin-proteasome system, proteasome inhibitors, cancer cell death, tumor xenografts, small molecule inhibitors, antitumour activity
- MeSH terms
- NEDD8 Protein, Animals, Antineoplastic Agents, Cells, Cultured, Cyclopentanes, Enzyme Inhibitors, Female, Humans, Neoplasms, Pyrimidines, Transplantation, Heterologous, Ubiquitins, Ubiquitin-Activating Enzymes, Cullin Proteins, Cell Line, Tumor, Mice, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.